Get the Stockscreener App
2.12
3.64%
-0.08
Cns Pharmaceuticals Inc stock is traded at $2.12, with a volume of 5,105.
It is down -3.64% in the last 24 hours and down -33.54% over the past month.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
See More
Previous Close:
$2.20
Open:
$2.24
24h Volume:
5,105
Relative Volume:
0.12
Market Cap:
$1.32M
Revenue:
-
Net Income/Loss:
$-13.07M
P/E Ratio:
-0.0521
EPS:
-40.717
Net Cash Flow:
$-16.23M
1W Performance:
-25.35%
1M Performance:
-33.54%
6M Performance:
-73.43%
1Y Performance:
-95.36%
1-Day Range:
$2.10
$2.24
1-Week Range:
$2.0573
$2.7748
52-Week Range:
$2.0573
$46.42
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
2.12 | 1.36M | 0 | -13.07M | -16.23M | -40.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.11 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.90 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
685.67 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.77 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.87 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
CNS Pharmaceuticals shifts focus to neurology, oncology assets By Investing.com - Investing.com Nigeria
Quarterly Trades: Is CNS Pharmaceuticals Inc currently under institutional pressure2026 Trading Recap & Long-Term Capital Growth Strategies - baoquankhu1.vn
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
CNS Pharmaceuticals Unveils Strategic Pivot to Broader Oncology - The Globe and Mail
CNS Pharmaceuticals shifts focus to neurology, oncology assets - Investing.com India
CNSP Implements New Strategy to Enhance Neurology and Oncology P - GuruFocus
CNS Pharmaceuticals Announces Strategic Shift to Neurology and Oncology Pipeline Expansion - citybuzz -
CNS Pharmaceuticals Launches Strategic Pivot Led by New Executive Team, Targeting High-Value Neurology and Oncology Assets for Investor Growth 123 - Minichart
CNS Pharmaceuticals (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology and Oncology Pipeline Expansion - Digital Journal
CNS Pharmaceuticals launches strategic pivot, names new executive team and begins asset search - TradingView
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline - ACCESS Newswire
New CNS Pharmaceuticals (NASDAQ: CNSP) team drives strategic pivot - Stock Titan
CNS Pharma shifts from single cancer focus to hunting new brain and tumor drugs - Stock Titan
Aug Final Week: Can CNS Pharmaceuticals Inc outperform under higher oil prices2026 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
CNS Pharmaceuticals (CNSP) Receives a Buy from Maxim Group - The Globe and Mail
Why is CNS Pharmaceuticals Inc stock going down2025 Price Momentum & Short-Term High Return Strategies - baoquankhu1.vn
CNSP Earnings History & Surprises | EPS & Revenue Results | CNS PHARMACEUTICALS INC (NASDAQ:CNSP) - ChartMill
9,500 RSUs awarded to CNS Pharmaceuticals (CNSP) CFO - Stock Titan
CNS Pharmaceuticals (CNSP) files insider Form 3 for Chief Financial Officer - Stock Titan
CNSP Financials: Income Statement, Balance Sheet & Cash Flow | CNS Pharmaceuticals - Stock Titan
CNS Pharmaceuticals (CNSP) awards CTO Eric Faulkner 9,500 RSUs - Stock Titan
CNS Pharmaceuticals Appoints New Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals names Lynne Kelley as chief medical officer By Investing.com - Investing.com Australia
CNS Pharmaceuticals (NASDAQ: CNSP) appoints new CMO Lynne Kelley - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints New Executive Leadership Team - Digital Journal
CNS Pharmaceuticals appoints Lynne Kelley as CMO - TipRanks
CNS Pharmaceuticals names Lynne Kelley as chief medical officer - Investing.com
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team - ACCESS Newswire
Brain cancer drug developer hires veteran surgeon to lead studies - Stock Titan
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm
Price Action: Will CNS Pharmaceuticals Inc stock go up in YEARGDP Growth & Smart Investment Allocation Tips - baoquankhu1.vn
Breakout Watch: Is CNS Pharmaceuticals Inc currently under institutional pressure2025 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn
Is CNS Pharmaceuticals Inc. forming a bullish divergence2025 AllTime Highs & Expert Verified Movement Alerts - mfd.ru
Drug-Delivery Breakthroughs, Cross-Indication Research - GlobeNewswire
Chart Watch: How does CNS Pharmaceuticals Inc perform in inflationary periodsGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
CNS Pharmaceuticals appoints three new executives to leadership team - Investing.com South Africa
CNS Pharmaceuticals appoints three new executives to leadership team By Investing.com - Investing.com Canada
CNS Pharmaceuticals Restructures Finance Leadership, Appoints New CFO - The Globe and Mail
ACADIA Pharmaceuticals Inc. (ACAD) Investor Outlook: Potential 41.67% Upside Amid Robust CNS Drug Portfolio - DirectorsTalk Interviews
CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO - TipRanks
CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 - marketscreener.com
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation - Yahoo Finance
Levels Update: Is CNS Pharmaceuticals Inc currently under institutional pressure2025 Performance Recap & Low Risk Growth Stock Ideas - baoquankhu1.vn
Is CNS Pharmaceuticals Inc. currently under institutional pressureFed Meeting & Free Long-Term Investment Growth Plans - mfd.ru
Is CNS Pharmaceuticals Inc. stock a smart buy before Fed meeting2025 Sector Review & Risk Managed Investment Strategies - mfd.ru
How CNS Pharmaceuticals Inc. stock performs in weak economy2025 Key Lessons & Stepwise Trade Signal Guides - mfd.ru
What are analysts’ price targets for CNS Pharmaceuticals Inc.July 2025 Opening Moves & Long Hold Capital Preservation Tips - mfd.ru
Why CNS Pharmaceuticals Inc. stock is recommended by analystsInsider Selling & Entry Point Strategy Guides - mfd.ru
CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 11.2% – Here’s What Happened - Defense World
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand - GlobeNewswire
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):